Drugs Industry (Pharmaceutical Industry)

The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs. The word pharmaceutical comes from the Greek word Pharmakeia. The modern transliteration of Pharmakeia is Pharmacia.

History
The earliest drugstores date to the Middle Ages. The first known drugstore was opened by Arabian pharmacists in Baghdad in 754, and many more soon began operating throughout the medieval Islamic world and eventually medieval Europe. By the 19th century, many of the drugstores in Europe and North America had eventually developed into larger pharmaceutical companies. Most of today's major pharmaceutical companies were founded in the late 19th and early 20th centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin, became mass-manufactured and distributed. Switzerland, Germany and Italy had particularly strong industries, with the UK, US, Belgium and the Netherlands following suit. Legislation was enacted to test and approve drugs and to require appropriate labeling. Prescription and non-prescription drugs became legally distinguished from one another as the pharmaceutical industry matured. The industry got underway in earnest from the 1950s, due to the development of systematic scientific approaches, understanding of human biology (including DNA) and sophisticated manufacturing techniques. Numerous new drugs were developed during the 1950s and mass-produced and marketed through the 1960s. These included the first oral contraceptive, "The Pill", Cortisone, bloodpressure drugs and other heart medications. MAO Inhibitors, chlorpromazine (Thorazine), Haldol (Haloperidol) and the tranquilizers ushered in the age of psychiatric medication. Valium (diazepam), discovered in 1960, was marketed from 1963 and rapidly became the most prescribed drug in history, prior to controversy over dependency and habituation. Attempts were made to increase regulation and to limit financial links between companies and prescribing physicians, including by the relatively new U.S. Food and Drug Administration (FDA). Such calls increased in the 1960s after the thalidomide tragedy came to light, in which the use of a new anti-emetic in pregnant women caused severe birth defects.

In 1964, the World Medical Association issued its Declaration of Helsinki, which set standards for clinical research and demanded that subjects give their informed consent before enrolling in an experiment. Pharmaceutical companies became required to prove efficacy in clinical trials before marketing drugs. Cancer drugs were a feature of the 1970s. From 1978, India took over as the primary center of pharmaceutical production without patent protection. The industry remained relatively small scale until the 1970s when it began to expand to a greater rate. Legislation allowing for strong patents, to cover both the process of manufacture and the specific products, came in to force in most countries. By the mid-1980s, small biotechnology firms were struggling for survival, which led to the formation of mutually beneficial partnerships with large pharmaceutical companies and a host of corporate buyouts of the smaller firms. Pharmaceutical manufacturing became concentrated, with a few large companies holding a dominant position throughout the world and with a few companies producing medicines within each country. The pharmaceutical industry entered the 1980s pressured by economics and a host of new regulations, both safety and environmental, but also transformed by new DNA chemistries and new technologies for analysis and computation. Drugs for heart disease and for AIDS were a feature of the 1980s, involving challenges to regulatory bodies and a faster approval process. Managed care and Health maintenance organizations (HMOs) spread during the 1980s as part of an effort to contain rising medical costs, and the development of preventative and maintenance medications became more important. A new business atmosphere became institutionalized in the 1990s, characterized by mergers and takeovers, and by a dramatic increase in the use of contract research organizations for clinical development and even for basic R&D. The pharmaceutical industry confronted a new business climate and new regulations, born in part from dealing with world market forces and protests by activists in developing countries. Animal Rights activism was also a challenge. Marketing changed dramatically in the 1990s. The Internet made possible the direct purchase of medicines by drug consumers and of raw materials by drug producers, transforming the nature of business. In the US, Direct-to-consumer advertising proliferated on radio and TV because of new FDA regulations in 1997 that liberalized requirements for the presentation of risks. The new antidepressants, the SSRIs, notably Fluoxetine (Prozac), rapidly became bestsellers and marketed for additional disorders. In the United States as of 2012, the industry spent about 1.3 percent of its revenue on research vs. about 25 percent on marketing.

Drug development progressed from a hit-and-miss approach to rational drug discovery in both laboratory design and natural-product surveys. Demand for nutritional supplements and so-called alternative medicines created new opportunities and increased competition in the industry. Controversies emerged around adverse effects, notably regarding Vioxx in the US, and marketing tactics. Pharmaceutical companies became increasingly accused of disease mongering or over-medicalizing personal or social problems.

Research and development

Drug discovery and Drug development Drug discovery is the process by which potential drugs are discovered or designed. In the past most drugs have been discovered either by isolating the active ingredient from traditional remedies or by serendipitous discovery. Modern biotechnology often focuses on understanding the metabolic pathways related to a disease state or pathogen, and manipulating these pathways using molecular biology or biochemistry. A great deal of earlystage drug discovery has traditionally been carried out by universities and research institutions. Public funding accounts for 80% of the amount spent on basic research for new drugs and vaccines in the United States. Drug development refers to activities undertaken after a compound is identified as a potential drug in order to establish its suitability as a medication. Objectives of drug development are to determine appropriate Formulation and Dosing, as well as to establish safety. Research in these areas generally includes a combination of in vitro studies, in vivo studies, and clinical trials. The amount of capital required for late stage development has made it a historical strength of the larger pharmaceutical companies. Suggested citation: Tufts Center for the Study of Drug Development, Annual Impact Report, Often, large multinational corporations exhibit vertical integration, participating in a broad range of drug discovery and development, manufacturing and quality control, marketing, sales, and distribution. Smaller organizations, on the other hand, often focus on a specific aspect such as discovering drug candidates or developing formulations. Often, collaborative agreements between research organizations and large pharmaceutical companies are formed to explore the potential of new drug substances. The cost of innovation Drug companies are like other companies in that they manufacture products that must be sold for a profit in order for the company to survive and grow. They are different from some companies because the drug business is very risky. For instance, only one out of every ten

thousand discovered compounds actually becomes an approved drug for sale. Much expense is incurred in the early phases of development of compounds that will not become approved drugs. In addition, it takes about 7 to 10 years and only 3 out of every 20 approved drugs bring in sufficient revenue to cover their developmental costs, and only 1 out of every 3 approved drugs generates enough money to cover the development costs of previous failures. This means that for a drug company to survive, it needs to discover a blockbuster (billiondollar drug) every few years. Drug discovery and development is very expensive; of all compounds investigated for use in humans only a small fraction are eventually approved in most nations by government appointed medical institutions or boards, who have to approve new drugs before they can be marketed in those countries. In 2010 18 NMEs (New Molecular Entities) were approved and three biologics by the FDA, or 21 in total, which is down from 26 in 2009 and 24 in 2008. On the other hand, there were only 18 approvals in total in 2007 and 22 back in 2006. Since 2001, the Center for Drug Evaluation and Research has averaged 22.9 approvals a year. This approval comes only after heavy investment in pre-clinical development and clinical trials, as well as a commitment to ongoing safety monitoring. Drugs which fail part-way through this process often incur large costs, while generating no revenue in return. If the cost of these failed drugs is taken into account, the cost of developing a successful new drug (New chemical entity or NCE), has been estimated at about 1.3 billion USD (not including marketing expenses). Professors Light and Lexchin reported in 2012, however, that the rate of approval for new drugs has been a relatively stable average rate of 15 to 25 for decades. Industry-wide research and investment reached a record $65.3 billion in 2009. While the cost of research in the U.S. was about $34.2 billion between 1995 and 2010, revenues rose faster (revenues rose by $200.4 billion in that time). A study by the consulting firm Bain & Company reported that the cost for discovering, developing and launching (which factored in marketing and other business expenses) a new drug (along with the prospective drugs that fail) rose over a five-year period to nearly $1.7 billion in 2003.

These estimates also take into account the opportunity cost of investing capital many years before revenues are realized (see Time-value of money). Because of the very long time needed for discovery, development, and approval of pharmaceuticals, these costs can accumulate to nearly half the total expense. Some approved drugs, such as those based on re-

formulation of an existing active ingredient (also referred to as Line-extensions) are much less expensive to develop. Calculations and claims in this area are controversial because of the implications for regulation and subsidization of the industry through tax credits and federally funded research grants. "Me-too" drugs Competition between pharmaceutical companies has resulted in "me-too" drugs, which are defined as chemically-similar compounds or compounds with the same mechanism of action as an existing, approved chemical entity. Critics of the pharma industry suggest that "me-too" drugs are only brought to market because their development is cheaper and less risky than drugs with a novel mechanism of action. However, proponents point to the cost benefits of market competition between similar drugs. In addition, it may take 10 or more years for a drug to go from discovery to FDA approval, and if a new clinical pathway is discovered, multiple companies often will simultaneously develop a drug treatment within this pathway, leading to several similar drugs arriving on the market within a short period of time. This is why some suggest that much of the me-too drug phenomenon is actually a result of independent parallel research at rival companies.

Pharmaceutical industry in India

The Pharmaceutical industry in India is the world's third-largest in terms of volume and stands 14th in terms of value. According to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion. While the domestic market was worth US$12.26 billion. Sale of all types of medicines in the country is expected to reach around US$19.22 billion by 2012. Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006-07 to US$8.7 billion in 2008-09 a combined annual growth rate of 21.25%. According to PricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion. Some of the major pharmaceutical firms including Sun Pharmaceutical, Cadila Healthcare and Piramal Healthcare. The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970.[4] However, economic liberalization in

the 1990s by the former Prime Minister P.V. Narasimha Rao and the then Finance Minister, Dr. Manmohan Singh enabled the industry to become what it is today. This patent act removed composition patents from food and drugs, and though it kept process patents, these were shortened to a period of five to seven years. The lack of patent protection made the Indian market undesirable to the multinational companies that had dominated the market, and while they streamed out. Indian companies carved a niche in both the Indian and world markets with their expertise in reverseengineering new processes for manufacturing drugs at low costs. Although some of the larger companies have taken baby steps towards drug innovation, the industry as a whole has been following this business model until the present. India's biopharmaceutical industry clocked a 17 percent growth with revenues of Rs.137 billion ($3 billion) in the 2009-10 financial year over the previous fiscal. Bio-pharma was the biggest contributor generating 60 percent of the industry's growth at Rs.8,829 crore, followed by bio-services at Rs.2,639 crore and bio-agri at Rs.1,936 crore. Top 20 Publicly Listed Life Science companies in India] Rank Company Revenue 2011 Revenue 2012

(USD until MARCH (USD

millions)

millions) 1 2 3 4 5 6 7 8 9 10 11 12 Abbott india ltd Ranbaxy Dr. Reddy's Laboratories Lupin Ltd Aurobindo Pharma Dabur Sun Pharmaceutical Cadila Healthcare Jubilant Lifesciences Piramal Healthcare GlaxoSmithKline Pharmaceuticals Ltd Ipca Laboratories 1348.51 1327.56 1178 929.84 865.19 700.3 673.99 629.45 561.03 480.26 475.8 390 --5,687.33 5,258.80 4,527.12 4,229.99 --1,985.78 2,213.17 ---

13 14 15 16 17 18 19 20

Wockhardt Torrent Pharmaceuticals Sterling Bio Biocon

381.23 380.2 358.1 340.38

Orchid Chemicals & Pharmaceuticals Limited 320.62 Alembic Aventis Pharma Glenmark Pharmaceuticals 270.62 263.75 260.14

Pharmaceutical industry today The number of purely Indian pharma companies is fairly low. Indian pharma industry is mainly operated as well as controlled by dominant foreign companies having subsidiaries in India due to availability of cheap labour in India at lowest cost. In 2002, over 20,000 registered drug manufacturers in India sold $9 billion worth of formulations and bulk drugs. 85% of these formulations were sold in India while over 60% of the bulk drugs were exported, mostly to the United States and Russia. Most of the players in the market are smallto-medium enterprises; 250 of the largest companies control 70% of the Indian market. Thanks to the 1970 Patent Act, multinationals represent only 35% of the market, down from 70% thirty years ago. Most pharma companies operating in India, even the multinationals, employ Indians almost exclusively from the lowest ranks to high level management. Mirroring the social structure, firms are very hierarchical. Homegrown pharmaceuticals, like many other businesses in India, are often a mix of public and private enterprise. Although many of these companies are publicly owned, leadership passes from father to son and the founding family holds a majority share. In terms of the global market, India currently holds a modest 1-2% share, but it has been growing at approximately 10% per year. India gained its foothold on the global scene with its innovatively engineered generic drugs and active pharmaceutical ingredients (API), and it is now seeking to become a major player in outsourced clinical research as well as contract manufacturing and research. There are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other country outside the U.S, and in 2005, almost 20% of all Abbreviated New Drug Applications (ANDA) to the FDA are expected to be filed by Indian companies. Growth in other fields notwithstanding, generics are still a large part of the

picture. London research company Global Insight estimates that Indias share of the global generics market will have risen from 4% to 33% by 2007. The Indian pharmaceutical industry has become the third largest producer in the world and is poised to grow into an industry of $ 20 billion in 2015 from the current turnover of $ 12 billion.

Top 20 Biopharmaceutical & Biotechnology companies in India, as of 2011 Rank Company Revenue 2011 crore) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Biocon Serum Institute of India Panacea Biotec Nuziveedu Seeds Private Limited Reliance Life Sciences Quintiles Novo Nordisk Rasi Seeds Mahyco Trans Asia Ankur Seeds Syngene International Bharat Biotech International Indian Immunologicals Limited Krishidhan Seeds Shantha Biotechnics Novozymes Bharat Serums Jubilant Lifesciences Eli Lilly and Company 1483 1041 928.41 610 490 476.25 462 371.88 364.9 350 325 318 298.34 283 276.13 272 242 226 210 204 Revenue (Rs 2011 millions) (USD

Patents

As it expands its core business, the industry is being forced to adapt its business model to recent changes in the operating environment. The first and most significant change was the January 1, 2005 enactment of an amendment to Indias patent law that reinstated product patents for the first time since 1972. The legislation took effect on the deadline set by the WTOs Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which mandated patent protection on both products and processes for a period of 20 years. Under this new law, India will be forced to recognize not only new patents but also any patents filed after January 1, 1995. Indian companies achieved their status in the domestic market by breaking these product patents, and it is estimated that within the next few years, they will lose $650 million of the local generics market to patent-holders. In the domestic market, this new patent legislation has resulted in fairly clear segmentation. The multinationals narrowed their focus onto high-end patients who make up only 12% of the market, taking advantage of their newly bestowed patent protection. Meanwhile, Indian firms have chosen to take their existing product portfolios and target semi-urban and rural populations. Multinational Pharmaceutical Companies ranked as per active presence of sales, marketing and business in India 1. Pfizer 2. GlaxoSmithKline 3. Sanofi Aventis 4. Merck 5. Johnson and Johnson 6. Amgen 7. Novartis 8. Roche 1. Bristol-Myers Squibb 2. Wyeth 3. Eli Lilly 4. Schering-Plough 5. Abbott 6. Takeda 7. Boehringer Ingelheim 8. Astellas

PLAYERS 1. Sun Pharmaceutical Industries Limited Snapshot Date of Establishment 1993

Revenue Market Cap Corporate Address

0 ( USD in Millions ) 769748.0671515 ( Rs. in Millions ) Sun Pharma Advanced Research Centre (S P A R C),Tandalja,Vadodara-390020, www.sunpharma.com Gujarat

Management Details

Chairperson MD -

Dilip

Israel S

Makov Shanghvi

Directors - Ashwin Dani, Dilip S Shanghvi, Hasmukh S Shah, Hasmukh Shah, Israel Makov, Kal Sundaram, Kamlesh H Shah, Keki M Mistry, S Kalyanasundaram, S Mohanchand Dadha, Sailesh T Desai, Sudhir V Valia, Sunil R Ajmera Business Operation Background Pharmaceuticals & Drugs Sun Pharmaceutical Industries began with just 5 products to treat psychiatry ailments in 1983. Sales were initially limited to 2 states - West Bengal and Bihar. Sales were rolled out nationally in 1985. Products that are used in cardiology were introduced in 1987, and Monotrate, one of the first products launched at that time has since become one of our largest selling products. Important products in Financials Total Income - Rs. 43801 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Bankers Auditors Deloittee Haskins & Sells Sunil R Ajmera

COMPANY HISTORY Sun Pharmaceutical Industries began with just 5 products to treat psychiatry ailments in 1983. Sales were initially limited to 2 states - West Bengal and Bihar. Sales were rolled out nationally in 1985. Products that are used in cardiology were introduced in 1987, and Monotrate, one of the first products launched at that time has since become one of our largest

selling products. Important products in Cardiology were then added; several of these were introduced for the first time in India. Sun Pharma was listed on the main stock exchanges in India in 1994. It is an international speciality pharma company, with a presence in 30 markets. It also make active pharmaceutical ingredients. In branded markets, its products are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. Realizing the fact that research is a critical growth driver, they established their research center SPARC in 1993 and this created a base of strong product and process development skills. In India, it has reached leadership in each of the therapy areas that we operate in, and are rated among the leading companies by key customers. Strengthening market share and keeping this customer focus remains a high priority area for the company. Another API plant, its Ahmednagar plant, was acquired from the multinational Knoll Pharmaceuticals in 1996, and upgraded for approvals from regulated markets, with substantial capacity addition over the years. This was the first of several sensibly priced acquisitions, each of which would bring important parts to the long-term strategy. With worldclass technology and a team of strong professionals, it has built sites and systems that meet the most stringent international manufacturing standards. Expert quality teams ensure that systems and processes remain in compliance with the latest standards. A number of its plants hold approvals from the USFDA and the UK MHRA. APIs and Dosage forms are made in 19 sites across India, US, Hungary and Bangladesh. Formulation - Sun Pharma is a market leader in speciality therapy areas, with high quality brands trusted for chronic disease. A comprehensive product basket and products with technology-based differentiation are highlights. It make speciality formulations across a range of dosage forms- oral, injectable and delivery system based. API- Its API (Active Pharmaceutical Ingredients) program began in 1995 with a simple objective - facilitating the manufacture of complex formulations, for which, sourcing the API would restrict entry. It make speciality APIs including peptides, steroids, hormones and anticancers at internationally approved worldclass sites. It has over 1600 registrations across 30 countries, over 1000 registrations filed and pending approval. In these countries, it uses the same approach to speciality brand building and customer focus that have worked for it in India. The company is engaged in manufacturing of product in the following therapy areas:

CNS disorders Cardiology

Diabetes and Metabolic disorders Gastroenterology Ophthalmology Oncology Pain Allergy, Asthma and Inflammation Gynecological

KEY EXECUTIVES No. 1 3 2 4 5 6 7 8 9 Name Israel Makov Dilip S Shanghvi Sunil R Ajmera S Mohanchand Dadha Hasmukh Shah Keki M Mistry Ashwin Dani Sudhir V Valia Sailesh T Desai Designation Chairman Managing Director Company Secretary Director Director Director Director Whole Time Director Whole Time Director

2. Piramal Healthcare Ltd

Snapshot Date of Establishment Revenue Market Cap Corporate Address 1947 0 ( USD in Millions ) 95427.3943 ( Rs. in Millions ) Piramal Tower,Ganpatrao Kadam Marg,Lower Maharashtra

ParelMumbai-400013, www.piramalhealthcare.com Management Details Chairperson MD Ajay G

Piramal -

Directors - Ajay G Piramal, Amit Chandra, Chanda Makhija Thadani, Deepak Satwalekar, Goverdhan

Mehta,

Keki

Dadiseth,

Leonard

D'souza,

Santhanam, N Vaghul, Nandini Piramal, R A Mashelkar, R A Shah, S Ramadorai, Swati A Piramal, Vijay Shah, Y H Malegam Business Operation Background Pharmaceuticals & Drugs Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to groups revenue. Besides healthcare, the Piramal Group has business interests in areas of glass manufacturing, retail and real estate.< Financials Total Income - Rs. 16879.1 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Bankers Leonard D'souza Allahabad Bank , Axis Bank , Bank of America, Calyon Bank, Citi Bank, Corporation Bank, HDFC Bank, HSBC Bank, ICICI Bank, ING Vysya Bank, Standard Chartered Bank, State Bank of Hyderabad Auditors Price Waterhouse

Company History Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to groups revenue. Besides healthcare, the Piramal Group has business interests in areas of glass manufacturing, retail and real estate. Piramal Healthcare operates two divisions namely healthcare solutions and pharma solutions. PHL is one of the largest custom manufacturing companies with global presence in North America, Europe and Asia. Manufacturing facilities Healthcare solutions- Headquartered in Mumbai, the company has manufacturing facilities located at Baddi in Himachal Pradesh and Mulund in Maharashtra.

Pharma solutions- PHLs manufacturing units are located at Mahad and Thane in Maharashtra, Ennore in Tamil Nadu, Digwal in Andhra Pradesh, Pithampur in Madhya Pradesh, Morpeth, Grangemouth, Huddersfield and Billingham in the U.K. and Torcan in Canada. Products and services Pharma Solutions- This division is engaged in manufacturing of API and formulations in nine therapeutic areas. The company operates one of the leading custom manufacturing businesses in the world, due to this PHL offers a full lifecycle partnership to small/virtual and big pharma. It provides services such as clinical phase APIs, clinical phase formulations and commercial APIs. It also offers packaging solutions. Healthcare solutions- Under this, PHL has developed multi-ingredient formulations and single-ingredients products. Outlook PHL has acquired US-based RxElite Holdings, the inhalation anaesthetic gas distribution arm of RxElite. The acquisition gives Piramal ownership of Holdings' sales and distribution network in the US.

Key Executives S.No 1 2 3 4 5 Name Ajay G Piramal Leonard D'souza Nandini Piramal Swati A Piramal Vijay Shah Designation Chairman Company Secretary Executive Director Vice Chairman Executive Director & Chief

Operating Officer 6 7 Chanda Makhija Thadani S Ramadorai Assistant Company Secretary Non Director 8 Deepak Satwalekar Non Director 9 R A Mashelkar Non Director 10 Goverdhan Mehta Non Executive Independent Executive Independent Executive Independent Executive Independent

Director 11 N Vaghul Non Director Executive Independent

3. Cipla Ltd.

Snapshot

Date of Establishment Revenue Market Cap Corporate Address

1935 0 ( USD in Millions ) 339876.6104181 ( Rs. in Millions ) Mumbai Central,,Mumbai-400008, Maharashtra

www.cipla.com Management Details Chairperson MD Y Y K K Hamied Hamied

Directors - Amar Lulla, H R Manchanda, K A Hamied, M K Hamied, M R Raghavan, Mital Sanghvi, Pankaj Patel, Ramesh Shroff, Ranjan Pai, S A A Pinto, S Radhakrishnan, Subhanu Saxena, V C Kotwal, Y K Hamied Business Operation Background Pharmaceuticals & Drugs Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated 1935.Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs. Financials Total Income - Rs. 71258 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Mital Sanghvi

Bankers

Bank of Baroda, Canara Bank , Corporation Bank, HSBC Bank, Indian Overseas Bank, Standard Chartered Bank, Union Bank of India

Auditors

RS Bharucha & Co, RGN Price & Co, V Sankar Aiyar & Co, RGN Price & Co

Company History Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated 1935.Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs. Business of the company: The company focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. Almost 55% of its overall income from its operations come from outside India. It has 5,500 registered products in various countries.Cipla offers drugs used for treatment of cancer, Alzheimer's, arthritis, Parkinsons, cardiovascular diesases and many more. It also offers drugs that prevents transmission of AIDS from mother to child.The company provides consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipments. Cipla has set up two institutes namely Dr K.A Hamied Institute and Cipla Cancer Palliative Care & Training Centre.It has a presence across 170 countries with manufacturing units approved by regulatory authorities like USFDA, WHO-Canada and MHRA-UK, among others. Cipla was first company outside US and Europe to launch CFC-free inhalers. In 2007 Cipla launched oral emergency contraceptive pill under the brand name I-Pill. Cipla also launched a breakthrough screening technology in India called the No Touch Breast Scan (NTBS); ' the first-ever painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage.

In 2009, Cipla launched generic versions of anti-flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza, spreading across the globe and in India. In 2010, Piramal Healthcare Limited announced the signing of a definitive agreement with Cipla Limited for purchase of all intellectual property rights in India related to 'i-pill' for an aggregate consideration of Rs 95 crore. Achievements: The company won the Forbes Asia's Best Under A Billion List from Forbes Magazine. Cipla also won the Most Profitable Company overall among those Under a Billion in the Regions Top 200 Small and Mid Size companies from Forbes Magazine. Key Executives S.No 1 3 2 4 5 6 7 8 9 10 11 12 Name Y K Hamied Y K Hamied Mital Sanghvi H R Manchanda Ramesh Shroff V C Kotwal M R Raghavan Pankaj Patel Ranjan Pai Subhanu Saxena M K Hamied S Radhakrishnan Designation Chairman Managing Director Company Secretary Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Chief Executive Officer Joint Managing Director Whole Time Director

4. Dredging Corpn. Of India Ltd Snapshot Date of Establishment Revenue Market Cap Corporate Address 1976 0 ( USD in Millions ) 6757.8 ( Rs. in Millions ) Core 2. 1st Floor,Scope Minar, Plot No 2 A & 2 B ,Laxmi Nagar District CenterNew Delhi-110092, Delhi

www.dredge-india.com Management Details Chairperson MD D D K K Mohanty Mohanty

Directors - A R Goyal, A Soundararaajan, AR Goyal, Aswini Sreekanth, D K Mohanty, Debashis Sanyal, G V Ratnam, Gautam Barua, K Aswini Sreekanth, MC Jauhari, Narasimha Rao, P Jayapal, P V Ramana Murthy, Rakesh Srivastava, S

Balachandran, S Narasimha Rao, S S Tripathi, Vinai Kumar Agarwal Business Operation Background Shipping Dredging Corporation of India Limited (DCI) was established in the year 1976 to provide dredging services to the major ports of the country in India. DCI is a pioneer organization in the field of dredging and maritime development. DCI is fully equipped to offer the complete range of dredging and allied services to the users in India and abroad and to provide vital inputs for the national development. Its h Financials Total Income - Rs. 5086.573 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Bankers Auditors Rao & Narayan, G R Kumar & Co. K Aswini Sreekanth

Company History Dredging Corporation of India Limited (DCI) was established in the year 1976 to provide dredging services to the major ports of the country in India. DCI is a pioneer organization in the field of dredging and maritime development. DCI is fully equipped to offer the complete range of dredging and allied services to the users in India and abroad and to provide vital inputs for the national development. Its head office is strategically situated on the east coast

of India at Visakhapatnam, DCI helps to ensure continuous availability of the desired depths in the shipping channels of the major and minor ports, Indian Navy, fishing harbors and other maritime organizations. It further serves the nation in a variety of ways, be it capital dredging for creation of new harbors, deepening of existing harbors or maintenance dredging for the upkeep of the required depths at various ports along the 7,500 Kms coastline of India. In 1977, DCI was awarded a $10 million contract for the management of Yanbu Construction Port on the Red Sea, 350 km north-west of Jeddah, Kingdom of Saudi Arabia, for three years. DCI's services included pilotage, tugging, berthing, unberthing and mooring of ocean-going cargo ships, supervision of cargo-handling operations, maintenance and upkeep of port facilities and establishment of 0 & M services. In addition to this, DCI has efficiently performed stevedoring services at Yanbu Construction Support Port during 1981-83. During the period 2001-02 DCI executed shore pumping and reclamation works at Taichung Harber, Taichung Taiwan. In September 2009, for the 18th consecutive year, Dredging Corporation of India has signed a memorandum of understanding with Government of India for the year 2009-10. The company expects the rating of 'Good' for the year 2008-2009. Other facts about the company:

DCI owns most modern and sophisticated fleet consisting of two Cutter Suction Dredgers and Ten Trailer Suction Dredgers.

DCI is an MoU signing company with the government of India. DCI is a schedule B & a Mini Ratna- Category-I public sector enterprise. DCI is one among the public sector undertakings of India in which the government has disinvested its share holding. The shares of the company are listed at Delhi, Bombay, Calcutta & National Stock Exchanges of India.

DCI's provides services that include:

pilotage tugging berthing unberthing and mooring of ocean-going cargo ships supervision of cargo-handling operations maintenance and upkeep of port facilities and establishment of O & M services.

In addition to this, DCI has efficiently performed stevedoring services at Yanbu Construction Support Port during 1981-83. During the period 2001-02 DCI executed shore pumping and reclamation works at Taichung Harber, Taichung Taiwan. Key Executives No. 1 3 2 4 5 6 7 8 9 10 Name D K Mohanty D K Mohanty K Aswini Sreekanth P Jayapal Rakesh Srivastava S Narasimha Rao S Balachandran Vinai Kumar Agarwal MC Jauhari P V Ramana Murthy Designation Chairman Managing Director Company Secretary Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Part Time Official Director Executive Director - Finance

5. Ranbaxy Laboratories Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1961 0 ( USD in Millions ) 216510.72144585 ( Rs. in Millions ) A-41, Industrial Area Phase V I I I - A,Sahibzada Ajit Singh Nagar, Mohali-160071, Punjab

www.ranbaxy.com Management Details Chairperson MD Tsutomu Arun Une Sawhney

Directors - Akihiro Watanabe, Anthony H Wild, Arun Sawhney, Atul Sobti, Kazunori Hirokawa, Percy K Shroff, Rajesh V Shah, S K Patawari, Sunil Godhwani, Takashi Shoda, Tsutomu Une Business Operation Background Pharmaceuticals & Drugs Ranbaxy Laboratories, is India's largest

pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.< Financials Total Income - Rs. 80382.68 Million ( year ending Dec 2011) Net Profit - Rs. Million ( year ending Dec 2011) Company Secretary Bankers S K Patawari ABN Amro Bank, Citi Bank, Deutsche Bank, HSBC Bank, Punjab National Bank, Standard Chartered Bank Auditors Walker, Chandiok & Co

Company History

Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries. Ranbaxy has world-class

manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam. Ranbaxy has its R & D centre that helps company to have long term competitive advantage. It caters treatment to segment of diseases that includes Cardiovascular, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology. Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatological, account for revenues of over $600 Million. Using the finest R&D and Manufacturing facilities, that manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, Active Pharmaceuticals and intermediates (API).

With workforce of over 12,000 spread across 50 nations, it pursues to become Global leader in pharma sector. In 2001 Ranbaxy entered consumer healthcare through launch of 4 brands Revital, Pepfiz, Gesdyp & Garlic Pearls. In 2004 launched its first herbal range of products through New Age Herbals (NAH), with products offering remedies in categories of Cough & Cold (Olesan Oil & Cough Syrups) and Appetite Stimulant (Eat Ease). In 2005, another popular brand, Chericof - The complete cough formula was introduced. During 2006, the business registered sales of $19 Million registering a growth of 19%. Revital, the flagship brand continues to maintain leadership in its segment. It also produces molecules like Simvastatin, Ciprofloxacin, Amoxycillin, Isotretinon and many more Key Executives S.No 1 3 2 4 5 6 7 8 9 Name Tsutomu Une Arun Sawhney S K Patawari Takashi Shoda Anthony H Wild Akihiro Watanabe Percy K Shroff Rajesh V Shah Kazunori Hirokawa Designation Chairman Managing Director Company Secretary Director Director Director Director Director Additional Director

6. Torrent Pharmaceuticals Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1972 0 ( USD in Millions ) 61753.601096 ( Rs. in Millions ) Torrent 380009, www.torrentpharma.com House,Off Ashram Road,AhmedabadGujarat

Management Details

Chairperson MD -

Sudhir Samir

Mehta Mehta

Directors - C Dutt, Chaitanya Dutt, Haigreve Khaitan, Kiran Karnik, Leena Srivastava, Mahesh Agrawal , Markand Bhatt, Mihir Thakore, Pradeep Bhargava, Prasanna Chandra, S H Bhojani, S Ramnarayan, Samir Mehta, Sanjay Lalbhai, Shailesh Haribhakti, Sudhir Mehta Business Operation Background Pharmaceuticals & Drugs Torrent Pharmaceuticals (TPL) was started in 1959 by U N Mehta as Trinity Laboratories. The company changed its name to present one in 1971. TPL is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments. Manufacturing facilities Its manufacturing f Financials Total Income - Rs. 22112.307 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Bankers Auditors Mahesh Agrawal No Bankers Details in A.R CC Chokshi & Co

Company History Torrent Pharmaceuticals (TPL) was started in 1959 by U N Mehta as Trinity Laboratories. The company changed its name to present one in 1971. TPL is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments. Manufacturing facilities

Its manufacturing facilities are located at Indrad (Gujarat) and Baddi (Himachal Pradesh). These units have received various certifications for its quality management such as ISO 9001, ISO 14001 and OHSAS 18001 and ISO/IEC- 17025. The companys Indrad plants manufactures bulk drugs, APIs, formulation in form of tablets, capsules and vials. It has annual production capacity of 6000 million kg of formulations and 15000 kg of bulk drugs/APIs. TPLs Baddi plant has a manufacturing capacity of 3600 million tablets, 400 million capsules and 18 million oral liquid bottles per annum. In India the company has 11 sales and marketing divisions. It has 1000 product registrations across 50 countries that includes US Latin America, Russia, Europe, Japan and many more. TPL's research and development department has a team of 560 scientists engaged in drug discovery, drug development and new drug delivery systems. The company has subsidiaries namely Zao Torrent Pharma (Russia), Torrent Do Brasil Ltda (Brazil), Torrent Pharma GmbH (Germany), Torrent Pharma Inc. (USA) and Torrent Pharma Philippines Inc. (Philippines). Awards Torrent Pharmaceuticals bagged the Gold Trophy at IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities. Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation. Outlook TPL launched Fibotab (Calcium Polycarbophil) for the first time in India. Fibotab is the first bulk laxative in a tablet forms and offers multiple benefits over conventional Isabgol options. Key Executives S.No 1 2 3 4 5 7 Name Sudhir Mehta Mahesh Agrawal Markand Bhatt Samir Mehta Pradeep Bhargava Prasanna Chandra Designation Chairman Company Secretary Non Executive Director Executive Vice Chairman Additional Director Non Director 8 Shailesh Haribhakti Non Executive Independent Executive Independent

Director 6 Sanjay Lalbhai Non Director 9 Leena Srivastava Independent Director 10 Haigreve Khaitan Independent Director 11 Chaitanya Dutt Whole Time Director Non-Executive Non-Executive Executive Independent

7. Cadila Healthcare Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1995 0 ( USD in Millions ) 183659.42244 ( Rs. in Millions ) Formulation Units,Zydus Tower,Satellite Cross Gujarat

RoadsAhmedabad-380015, www.zyduscadila.com Management Details Chairperson MD Pankaj Pankaj R R

Patel Patel

Directors - Apurva S Diwanji, H K Bilpodiwala, Humayun Dhanrajgir, Mukesh M Patel, Nitin Raojibhai Desai, Pankaj R Patel, Pranlal Bhogilal, Sharvil P Patel, Upen H Shah Business Operation Background Pharmaceuticals & Drugs Cadila Healthcare (CHL), incorporated in 1995, is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical

ingredients (API) to formulations, and animal health products to cosmeceuticals.Cadila Pharmaceuticals Ltd. is one of the largest privately held

pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat. Over the last five decade

Financials

Total Income - Rs. 33933 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012)

Company Secretary Bankers Auditors

Upen H Shah

Mukesh M Shah & Co

Company History Cadila Healthcare (CHL), incorporated in 1995, is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and

immunologicals. The company focuses on providing high quality, appropriately priced products to its customers and supports all these with dedicated customer service. Cadila Pharmaceuticals has a multicultural, multilingual and multinational workforce of more than four thousand employees including over two hundred people outside India in forty-nine countries of Africa, CIS, Japan and USA. The companys headquarter is located at Ahmedabad. CHL operates eight manufacturing facilities out of which four formulation plants are located at Ahmedabad, Goa, Baddi and Sikkim. The company has state-of-the-art manufacturing facilities conforming to the most stringent international cGMP norms vis--vis WHO-GMP, WHO, Geneva (GDF site for Anti- TB), TGA Australia (PIC/S), USFDA, UK- MHRA, MCC-South Africa, ISO 9001 and ISO 14001. Spread over hundred acres of land, Cadila Pharmaceuticals manufacturing facility at Dholka is the cynosure of all eyes, well equipped with world-class production facilities. The companys two Active Pharmaceutical Ingredients units at Ankleshwar manufacture a wide-range of APIs and intermediates including three USFDA certified products. The manufacturing facility at Samba, near Jammu, started its commercial operations in August 2006. The first overseas formulation manufacturing facility of

Cadila Ethiopia.

Pharmaceuticals Ltd. has commenced its operations in

The Zydus Cadila Group operates in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets. The company has in-licensing alliances with global multinationals such as Schering AG, Boehringer Ingelheim, Viatris, etc. Key Executives S.No 1 3 2 4 5 Name Pankaj R Patel Pankaj R Patel Upen H Shah Sharvil P Patel Humayun Dhanrajgir Designation Chairman Managing Director Company Secretary Deputy Managing Director Non Executive & Independent Director 6 Mukesh M Patel Non Executive & Independent Director 7 Nitin Raojibhai Desai Non Executive & Independent Director 8 Apurva S Diwanji Non Executive & Independent Director

8. GlaxoSmithKline Pharmaceuticals Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1924 0 ( USD in Millions ) 184910.92126185 ( Rs. in Millions ) Dr Annie Besant Road,Worli,Mumbai-400030,

Maharashtra www.gsk-india.com Management Details Chairperson MD H D B S Parekh Joshipura

Directors - A A Nadkarni, A Banerjee, A M

Nimbalkar, A N Roy, AA Nadkarni, B Kapadia, C T Renganathan, D S Parekh, D Sundaram, H B Joshipura, H Buch, K Vasanth Kumar, M B Kapadia, M Reilly, N Kaviratne, N Kaviratne ( C B E ), P V Nayak, PV Bhide, R Bartaria, R C Sequeira, R Krishnaswamy, R R Bajaaj, Raju Krishnaswamy, S Harford, S Joglekar, S Khanna, S Patel, V Narayanan, V Thyagarajan Business Operation Background Pharmaceuticals & Drugs Established in the year 1924 in India,

GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3,500 people. Globally, the company is a 28.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs 2080 crore and a share of 5.1%. GlaxoSmithKline one of Financials Total Income - Rs. 26177.961 Million ( year ending Dec 2011) Net Profit - Rs. Million ( year ending Dec 2011) Company Secretary Bankers Auditors Price Waterhouse & Co AA Nadkarni

Company History Established in the year 1924 in India, GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3,500 people. Globally, the company is a 28.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs 2080 crore and a share of 5.1%. GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

The company leads in several therapeutic segments - dermatology, anti-helmentics, and hormones. It has 7 products in the top 50 brands, and the top five GSK products are Augmentin, Calpol, Ceftum, Phexin, and Betnesol. The company's vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix, Rotarix, Hiberix and Cervarix. GSK India's R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India. The number of clinical studies conducted in India is rapidly growing across a range of therapy areas. The company's social responsibility programmes focus on development of under developed villages, women, children and aged, specifically in the areas of healthcare and education. The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others. The company's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. The company has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk drugs and the active pharmaceutical ingredients are manufactured at Thane.

Key Executives No. 1 3 2 4 5 6 7 8 Name D S Parekh H B Joshipura AA Nadkarni S Harford B Kapadia R Krishnaswamy V Thyagarajan PV Bhide Designation Chairman Managing Director Company Secretary Director Executive Director Executive Director Vice Chairman Non Executive Independent

Director 10 A N Roy Independent Director 13 D Sundaram Independent Director 14 N Kaviratne ( C B E ) Independent Director 15 P V Nayak Independent Director 9 R C Sequeira Independent Director 11 R R Bajaaj Independent Director 12 PV Bhide Independent Director Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive

9. Lupin Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1983 0 ( USD in Millions ) 268112.95935 ( Rs. in Millions ) 159 C S T Road,Kalina Santacruz (East), Mumbai400098, www.lupinworld.com Management Details Chairperson MD Desh Kamal Bandhu K Gupta Sharma Maharashtra

Directors - D K Contractor, Desh Bandhu Gupta, Dileep C Choksi, K U Mada, K V Kamath, K V Kamoth, Kamal K Sharma, M D Gupta, Marc Desaedeleer, Nilesh Gupta, R A Shah, R V Satam, Richard Zahn, Sunil Nair, Vijay Kelkar, Vinita Gupta Business Operation Pharmaceuticals & Drugs

Background

Lupin is a transnational company engaged in development formulations. It is the largest manufacturer of Tuberculosis drugs in the world having onshore and offshore presence of its products in 70 countries. Its manufacturing unit is located in Goa, Tarapur, Ankleshwar, Jammu, Mandideep, In of APIs, generic and branded

Financials

Total Income - Rs. 53883.2 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012)

Company Secretary Bankers

R V Satam Bank of Baroda, Central Bank of India, Citi Bank, Hongkong Bank, HSBC Bank, ICICI Bank, JP Morgan Chase Bank, Kotak Mahindra Bank, Standard Chartered Bank, State Bank of India

Auditors

Deloittee Haskins & Sells

Company History Lupin is a transnational company engaged in development of APIs, generic and branded formulations. It is the largest manufacturer of Tuberculosis drugs in the world having onshore and offshore presence of its products in 70 countries. Its manufacturing unit is located in Goa, Tarapur, Ankleshwar, Jammu, Mandideep, Indore, Aurangabad and Kyowa in Japan. The manufacturing facilities of the company are approved by various international regulatory agencies like US FDA, UK MHRA, TGA Australia, WHO, and MCC South Africa. Business In formulations it offers wide range of products for treatment of Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and many more. It constitutes 70% of Lupins business .It has presence in USA, Europe, Japan, Australia and emerging markets of India and some of the other rest of world countries.

In APIs segement it has a basket of product offerings for treatment of TB, Cardiovasculars, Cephalosporins and many more. In CRAMS (Contract Research and Manufacturing Services) space, it has acquired Novodigm who is engaged into developing and validating of products Key Executives S.No 1 3 2 4 5 6 7 Name Desh Bandhu Gupta Kamal K Sharma R V Satam M D Gupta Nilesh Gupta Dileep C Choksi Vinita Gupta Designation Chairman Managing Director Company Secretary Executive Director Executive Director Additional Director Promoter Director 8 Vijay Kelkar Independent Director 9 Richard Zahn Independent Director 10 R A Shah Independent Director 11 K U Mada Independent Director Non-Executive Non-Executive Non-Executive Non-Executive & Non-Executive

10. Glenmark Pharmaceuticals Limited Snapshot Date of Establishment Revenue Market Cap Corporate Address 1977 0 ( USD in Millions ) 141541.6449884 ( Rs. in Millions ) B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, Mumbai-400026, Maharashtra

www.glenmarkpharma.com Management Details Chairperson Glenn Saldanha

MD

Glenn

Saldanha

Directors - A S Mohanty, B E Saldanha, Bernard Munos, Brian W Tempest, Cheryl Pinto, Cherylann Pinto, D R Mehta, Glenn Saldanha, Gracias Saldanha, Hocine Sidi Said, J F Ribeiro, Julio F Ribeiro, M Gopal Krishnan, Marshall Mendonza, N B Desai, R V Desai, Rajesh V Desai, Sridhar Gorthi Business Operation Background Pharmaceuticals & Drugs Glenmark Pharmaceuticals was incorporated in 1977, entered into the dermatology market by 1979 through the launch of its Candid Cream. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. It operates in the formulation business in over 95 countries that includes India. Financials Total Income - Rs. 16750.84 Million ( year ending Mar 2012) Net Profit - Rs. Million ( year ending Mar 2012) Company Secretary Bankers Auditors Price Waterhouse & Co Marshall Mendonza

Company History Glenmark Pharmaceuticals was incorporated in 1977, entered into the dermatology market by 1979 through the launch of its Candid Cream. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. It operates in the formulation business in over 95 countries that includes India. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000

people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres. Glenmark was chosen as the Best Pharma Company in the World - SME and Best Company across emerging markets for 2008 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. Forbes, another leading international publication, recognized Glenmark as the Best under a Billion Dollar companies in Asia for 2008. Recently, the company also received recognitions for being the Indian Innovator Pharmaceutical Company of the Year and a Silver Patent Award in NCE / Drug Discovery Patent Category by Frost & Sullivan and Pharmexcil respectively Business area of the company Specialty Business: Drug Discovery: Glenmarks ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Glenmark has a robust pipeline of 13 molecules in various stages of preclinical & clinical development. Of these, eight molecules are in clinical trials. The molecules in clinical development are focusing on advanced treatments for chronic/debilitating diseases and are potential blockbusters with potential peak sales opportunity for each molecule being in the range of $1 billion to $3 billion. Simultaneously, Glenmark has actively followed the strategy of out-licensing its molecules in clinical development to large multinational pharmaceutical organizations. This out licensing strategy has been successful so far with four deals struck by the organization in the last five years collecting $115 million (around Rs 500 crore) as upfront and milestone payments. This business has three dedicated R&D centres. Discovery research for New Chemical Entities (NCEs) is carried out at its state-of-the-art research centre at Navi Mumbai, India. Over 200 scientists are employed at this research centre. It is a complete end to end setup with expertise in all areas of NCE (new chemical entity) discovery and development ranging from target selection to clinical development. Glenmarks biopharmaceutical research is carried out at its R&D facility in Switzerland. The centre is dedicated to the discovery and development of novel monoclonal antibodies (mAbs). The R&D centre has capabilities to develop mAbs from inception through to preclinical and clinical studies. Glenmark has also invested in another state-of-the-art R&D facility in Oxford, UK for molecules in clinical development. The R&D facility will serve as Glenmarks global centre for clinical development for both small molecules (NCEs) and biologics (NBEs). Specialty Business:

Formulations Business: Glenmarks formulations business is currently organized around four regions India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets. Key Executives S.No 1 2 3 4 5 6 7 8 9 10 11 12 Name Glenn Saldanha Glenn Saldanha Cherylann Pinto Rajesh V Desai B E Saldanha D R Mehta Bernard Munos Brian W Tempest Julio F Ribeiro Hocine Sidi Said Sridhar Gorthi N B Desai Designation Chairman Managing Director Executive Director Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director Non Executive Director